Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | HPGD | P15428 | 3/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161523 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL5421230 | 0.88 | SMN1; SMN2 (0.78) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL2090792 | 0.85 | RAB9A (0.74) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL7619684 | 0.84 | MAPT (0.72) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL5461064 | 0.84 | RAB9A (0.77) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL3190375 | 0.83 | MAPT (0.71) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL2242816 | 0.83 | KDM4E (1.00) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL12687369 | 0.82 | MAPT (0.69) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL14742583 | 0.82 | MAPT (0.69) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 | |
| SCHEMBL6204792 | 0.81 | SMN1; SMN2 (0.81) | MAPTSMN1; SMN2RAB9ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047723-A | Process for preparing benzoazacyclic compounds | 常州大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-115739190-B | Metal complex catalyst for phytic acid and preparation method and application thereof | 江南大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-115057830-B | Method for synthesizing 2-aryl benzothiazole | 辽宁科技大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115739190-A | Phytic acid metal complex catalyst and preparation method and application thereof | 江南大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-111793040-B | Preparation method of 2-substituted benzothiazole | 太原理工大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-111793040-A | Preparation method of 2-substituted benzothiazole | 太原理工大学 | 2020-10-20 | — | — | CN | disclosed |
| WO-2019144845-A1 | SPIRO-CONTAINING PLATINUM (II) EMITTERS WITH TUNABLE EMISSION ENERGIES AND SYNTHESES THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2019-08-01 | — | — | WO | disclosed |
| CN-105859652-B | Yb/MCM-41 molecular sieve catalyst catalyzes and synthesizes the method that 2- replaces benzothiazole compound | 同济大学 | 2019-03-01 | — | — | CN | disclosed |
| CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 福建医科大学 | 2019-01-11 | — | — | CN | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| CN-103073520-A | Method for synthesizing 2-phenyl benzothiazole and derivative thereof | UNIV HUNAN | 2013-05-01 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | MAPT 3113/4885SMN1; SMN2 4/4885RAB9A 3748/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MAPT 4299/4885SMN1; SMN2 3787/4885RAB9A 3153/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | MAPT 4858/4885SMN1; SMN2 9/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.